283 related articles for article (PubMed ID: 21816908)
1. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.
Bitler BG; Nicodemus JP; Li H; Cai Q; Wu H; Hua X; Li T; Birrer MJ; Godwin AK; Cairns P; Zhang R
Cancer Res; 2011 Oct; 71(19):6184-94. PubMed ID: 21816908
[TBL] [Abstract][Full Text] [Related]
2. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidic Acid Initiates Epithelial to Mesenchymal Transition and Induces β-Catenin-mediated Transcription in Epithelial Ovarian Carcinoma.
Burkhalter RJ; Westfall SD; Liu Y; Stack MS
J Biol Chem; 2015 Sep; 290(36):22143-54. PubMed ID: 26175151
[TBL] [Abstract][Full Text] [Related]
4. Wnt5a influences viability, migration, adhesion, colony formation, E- and N-cadherin expression of human ovarian cancer cell line SKOV-3.
Jannesari-Ladani F; Hossein G; Monhasery N; Shahoei SH; Izadi Mood N
Folia Biol (Praha); 2014; 60(2):57-67. PubMed ID: 24785108
[TBL] [Abstract][Full Text] [Related]
5. Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Cα in epithelial ovarian cancer.
Qi H; Sun B; Zhao X; Du J; Gu Q; Liu Y; Cheng R; Dong X
Oncol Rep; 2014 Aug; 32(2):771-9. PubMed ID: 24898696
[TBL] [Abstract][Full Text] [Related]
6. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.
Duan H; Yan Z; Chen W; Wu Y; Han J; Guo H; Qiao J
Gynecol Oncol; 2017 Nov; 147(2):408-417. PubMed ID: 28851501
[TBL] [Abstract][Full Text] [Related]
7. The Role of Abnormal Methylation of Wnt5a Gene Promoter Regions in Human Epithelial Ovarian Cancer: A Clinical and Experimental Study.
Jin P; Song Y; Yu G
Anal Cell Pathol (Amst); 2018; 2018():6567081. PubMed ID: 30079293
[TBL] [Abstract][Full Text] [Related]
8. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells.
Garipov A; Li H; Bitler BG; Thapa RJ; Balachandran S; Zhang R
Mol Cancer Res; 2013 Apr; 11(4):360-9. PubMed ID: 23360797
[TBL] [Abstract][Full Text] [Related]
9. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.
Li H; Cai Q; Wu H; Vathipadiekal V; Dobbin ZC; Li T; Hua X; Landen CN; Birrer MJ; Sánchez-Beato M; Zhang R
Mol Cancer Res; 2012 Nov; 10(11):1462-72. PubMed ID: 22964433
[TBL] [Abstract][Full Text] [Related]
10. Capn4 Enhances Osteopontin Expression through Activation of the Wnt/β-Catenin Pathway to Promote Epithelial Ovarian Carcinoma Metastasis.
Yang X; Sun J; Xia D; Can X; Liu L; Zhang J; Xu H; Du N; Liu W; Shen F; Zhang Z; Sun Y; Xi X
Cell Physiol Biochem; 2017; 42(1):185-197. PubMed ID: 28535511
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
12. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer.
Peng C; Zhang X; Yu H; Wu D; Zheng J
Int J Gynecol Cancer; 2011 Feb; 21(2):280-8. PubMed ID: 21270611
[TBL] [Abstract][Full Text] [Related]
13. Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.
Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C
Oncotarget; 2015 Nov; 6(37):40310-26. PubMed ID: 26515598
[TBL] [Abstract][Full Text] [Related]
14. The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma.
Chen S; Wang J; Gou WF; Xiu YL; Zheng HC; Zong ZH; Takano Y; Zhao Y
Int J Mol Sci; 2013 Dec; 14(12):24187-99. PubMed ID: 24351810
[TBL] [Abstract][Full Text] [Related]
15. The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer.
Ford CE; Punnia-Moorthy G; Henry CE; Llamosas E; Nixdorf S; Olivier J; Caduff R; Ward RL; Heinzelmann-Schwarz V
Gynecol Oncol; 2014 Aug; 134(2):338-45. PubMed ID: 24924122
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.
Peng DX; Luo M; Qiu LW; He YL; Wang XF
Oncol Rep; 2012 Apr; 27(4):1238-44. PubMed ID: 22246341
[TBL] [Abstract][Full Text] [Related]
17. Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer.
O'Shannessy DJ; Jackson SM; Twine NC; Hoffman BE; Dezso Z; Agoulnik SI; Somers EB
Int J Mol Sci; 2013 Jul; 14(7):13687-703. PubMed ID: 23880844
[TBL] [Abstract][Full Text] [Related]
18. Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition.
Cheng R; Sun B; Liu Z; Zhao X; Qi L; Li Y; Gu Q
J Cell Physiol; 2014 Dec; 229(12):1908-17. PubMed ID: 24464650
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
20. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
Badiglian Filho L; Oshima CT; De Oliveira Lima F; De Oliveira Costa H; De Sousa Damião R; Gomes TS; Gonçalves WJ
Oncol Rep; 2009 Feb; 21(2):313-20. PubMed ID: 19148501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
